These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 33403051)

  • 1. The added value of CA125 normalization before interval debulking surgery to the chemotherapy response score for the prognostication of ovarian cancer patients receiving neoadjuvant chemotherapy for advanced disease.
    Liang WF; Wang LJ; Li H; Liu CH; Wu MF; Li J
    J Cancer; 2021; 12(3):946-953. PubMed ID: 33403051
    [No Abstract]   [Full Text] [Related]  

  • 2. [Analysis of factors related to the prognostic benefit of neoadjuvant chemotherapy followed by interval debulking surgery in patients with advanced ovarian cancer].
    Wang DF; Zhang GN; Peng CR; Shi Y; Shi XW
    Zhonghua Fu Chan Ke Za Zhi; 2021 Jun; 56(6):385-392. PubMed ID: 34154313
    [No Abstract]   [Full Text] [Related]  

  • 3. Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data.
    Cohen PA; Powell A; Böhm S; Gilks CB; Stewart CJR; Meniawy TM; Bulsara M; Avril S; Brockbank EC; Bosse T; de Azevedo Focchi GR; Ganesan R; Glasspool RM; Howitt BE; Kim HS; Lee JY; Le ND; Lockley M; Manchanda R; Mandalia T; McCluggage WG; McNeish I; Midha D; Srinivasan R; Tan YY; van der Griend R; Yunokawa M; Zannoni GF; ; Singh N
    Gynecol Oncol; 2019 Aug; 154(2):441-448. PubMed ID: 31118141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. External validation of a 'response score' after neoadjuvant chemotherapy in patients with high-grade serous ovarian carcinoma with complete clinical response.
    Zorzato PC; Zannoni GF; Tudisco R; Pasciuto T; Di Giorgio A; Franchi M; Scambia G; Fagotti A
    Int J Gynecol Cancer; 2020 Jan; 30(1):67-73. PubMed ID: 31754067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals.
    Kobal B; Noventa M; Cvjeticanin B; Barbic M; Meglic L; Herzog M; Bordi G; Vitagliano A; Saccardi C; Skof E
    Radiol Oncol; 2018 Sep; 52(3):307-319. PubMed ID: 30210049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Choosing the right timing for interval debulking surgery and perioperative chemotherapy may improve the prognosis of advanced epithelial ovarian cancer: a retrospective study.
    Wang D; Zhang G; Peng C; Shi Y; Shi X
    J Ovarian Res; 2021 Mar; 14(1):49. PubMed ID: 33771198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutrophil-to-lymphocyte ratio and chemotherapy response score as prognostic markers in ovarian cancer patients treated with neoadjuvant chemotherapy.
    Liontos M; Andrikopoulou A; Koutsoukos K; Markellos C; Skafida E; Fiste O; Kaparelou M; Thomakos N; Haidopoulos D; Rodolakis A; Dimopoulos MA; Zagouri F
    J Ovarian Res; 2021 Nov; 14(1):148. PubMed ID: 34724958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of Ovarian Cancer Patients Most Likely to Achieve Chemotherapy Response Score 3 Following Neoadjuvant Chemotherapy: Development of a Predictive Nomogram.
    Liang WF; Li H; Wu JY; Liu CH; Wu MF; Li J
    Front Oncol; 2020; 10():560888. PubMed ID: 33123471
    [No Abstract]   [Full Text] [Related]  

  • 9. Prognostic Value of Ki67 in Epithelial Ovarian Cancer: Post-Neoadjuvant Chemotherapy Ki67 Combined with CA125 Predicting Recurrence.
    Liu Y; Gu Q; Xiao Y; Wei X; Wang J; Huang X; Linghu H
    Cancer Manag Res; 2024; 16():761-769. PubMed ID: 39006376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum CA125 levels predict outcome of interval debulking surgery after neoadjuvant chemotherapy in patients with advanced ovarian cancer.
    Zhang D; Jiang YX; Luo SJ; Zhou R; Jiang QX; Linghu H
    Clin Chim Acta; 2018 Sep; 484():32-35. PubMed ID: 29702068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Chemotherapy Response Score with Multidrug Resistance 1 and CA125 ELIMination Rate Constant K in Patients with Advanced Ovarian Cancer Treated with Neoadjuvant Chemotherapy.
    Matsukuma K; Nishio S; Tasaki S; Park J; Nasu H; Yoshimitsu T; Tasaki K; Katsuda T; Terada A; Tsuda N; Sanada S; Ushijima K
    Kurume Med J; 2024 Jul; 70(1.2):29-37. PubMed ID: 38556270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum HE4 and CA125 as predictors of response and outcome during neoadjuvant chemotherapy of advanced high-grade serous ovarian cancer.
    Vallius T; Hynninen J; Auranen A; Carpén O; Matomäki J; Oksa S; Virtanen J; Grénman S
    Tumour Biol; 2014 Dec; 35(12):12389-95. PubMed ID: 25190018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal Time Interval between Neoadjuvant Platinum-Based Chemotherapy and Interval Debulking Surgery in High-Grade Serous Ovarian Cancer.
    Andrikopoulou A; Theofanakis C; Markellos C; Kaparelou M; Koutsoukos K; Apostolidou K; Thomakos N; Haidopoulos D; Rodolakis A; Dimopoulos MA; Zagouri F; Liontos M
    Cancers (Basel); 2023 Jul; 15(13):. PubMed ID: 37444629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection.
    Gill SE; McGree ME; Weaver AL; Cliby WA; Langstraat CL
    Gynecol Oncol; 2017 Feb; 144(2):266-273. PubMed ID: 27916269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response evaluation after neoadjuvant therapy: evaluation of chemotherapy response score and serological and/or radiological assessment of response in ovarian cancer patients.
    Ramspott JP; Baert T; MacKintosh ML; Traut A; Ataseven B; Bommert M; Heitz F; Plett H; Schneider S; Waltering KU; Heikaus S; Harter P; du Bois A
    Arch Gynecol Obstet; 2021 Oct; 304(4):1021-1032. PubMed ID: 33661392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of neoadjuvant hyperthermic intraperitoneal chemotherapy on chemotherapy response score and recurrence in high-grade serous ovarian cancer patients with advanced disease: A multicentre retrospective cohort study.
    Wu MF; Liang JX; Li H; Ye YF; Liang WF; Wang LJ; Zhang BZ; Chen Q; Lin ZQ; Li J
    BJOG; 2022 Nov; 129 Suppl 2():5-13. PubMed ID: 36485072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The chemotherapy response score is a useful histological predictor of prognosis in high-grade serous carcinoma.
    Singh P; Kaushal V; Rai B; Rajwanshi A; Gupta N; Dey P; Garg R; Rohilla M; Suri V; Ghoshal S; Srinivasan R
    Histopathology; 2018 Mar; 72(4):619-625. PubMed ID: 28914967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic impact of microscopic residual disease after neoadjuvant chemotherapy in patients undergoing interval debulking surgery for advanced ovarian cancer.
    Di Donato V; Caruso G; Golia D'Augè T; Perniola G; Palaia I; Tomao F; Muzii L; Pernazza A; Della Rocca C; Bogani G; Benedetti Panici P; Giannini A
    Arch Gynecol Obstet; 2024 Oct; ():. PubMed ID: 39397086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Ki-67 Labeling Index on Prognostic Significance of the Chemotherapy Response Score in Women With Tubo-ovarian Cancer Treated With Neoadjuvant Chemotherapy.
    Heayn M; Skvarca LB; Zhu L; Edwards RP; Olawaiye AB; Modugno F; Elishaev E; Bhargava R
    Int J Gynecol Pathol; 2021 May; 40(3):278-285. PubMed ID: 32897953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histopathologic response to neoadjuvant chemotherapy as a prognostic biomarker in tubo-ovarian high-grade serous carcinoma: updated Chemotherapy Response Score (CRS) results.
    Böhm S; Le N; Lockley M; Brockbank E; Faruqi A; Said I; Jeyarajah A; Wuntakal R; Gilks B; Singh N
    Int J Gynecol Cancer; 2019 Feb; 29(2):353-356. PubMed ID: 30683759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.